Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases
| Autor: | Deepak Devidas Sonawane, Ashish Y. Pawar, Yogesh Suresh Ahire, Apoorva Prashant Hiray, Rajendra Sudhakar Bhambar, Deelip V. Derle |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Convalescent plasma Endocrinology Diabetes and Metabolism Pneumonia Viral ACE2 Comorbidity Article Diabetes Complications Betacoronavirus 03 medical and health sciences 0302 clinical medicine Clinical Protocols Diabetes mellitus Pandemic Internal Medicine Humans Medicine 030212 general & internal medicine Intensive care medicine Adverse effect Pandemics COVID-19 Serotherapy Randomized Controlled Trials as Topic SARS-CoV-2 business.industry Liver Diseases Diabetes Immunization Passive COVID-19 General Medicine medicine.disease Clinical trial 030104 developmental biology Neutralizing Antibodies Viral disease Coronavirus Infections business Literature survey |
| Zdroj: | Diabetes & Metabolic Syndrome: Clinical Research & Reviews Diabetes & Metabolic Syndrome |
| ISSN: | 1871-4021 |
| Popis: | Background & Aim As on date, no specific treatment is available for devastating COVID-19 (SARS-CoV-2) infection. This pandemic viral infection has affected over 200 countries within a very short time and created a calamitous situationacross the globe. As per WHO guidelines, the treatment is mainly symptomatic andsupportive. This clinical protocol has not proven sufficient to save the lives of COVID-19 patients suffering from diabetes or having underlying liver diseases; hence there isutmost need to tackle this situation by other means such as Convalescent Plasma (CP)therapy. Methods A comprehensive literature survey was carriedout using Elsevier, PubMed, Taylor & Francis, Springer, Nature and Google searchengines. Results The patients suffering from diabetes or liverdysfunction or any other underlying diseases are at greatest risk of SARS-CoV-2infection. From the study, it is proved that plasma collected from the recovered patientsof viral infection has considerable potential to treat the viral disease without theoccurrence of adverse effects. Conclusion The CP therapy can bea possible life saving alternative to treat critical COVID-19 patients having diabetes orunderlying liver dysfunction. Hence, randomised clinical trials are recommended at theearliest to save the lives of infected individuals of COVID-19. Graphical abstract Image 1 Highlights • In the absence of a proven antiviral treatment, convalescent plasma is a promising treatment for COVID-19. • Ongoing trials of convalescent plasma are likely to clarify its role in treating patients with COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect